# Rytary - (23.75/95mg, 36.25/145mg, 48.75/195mg; Capsule, extended release)

| Generic Name | Carbidopa and Levodopa | Innovator | Impax |
|---|---|---|---|
| Dosage | 23.75/95mg, 36.25/145mg, 48.75/195mg; Capsule, extended release | Branded US Sales | Less Than $1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | Less Than 5 |
| Indication | Indicated for Parikinson's disease. | | |
| Complexities | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

# Rytary - (61.25mg/ 245mg Capsule, extended release)

| | | | |
|---|---|---|---|
| **Generic Name** | Carbidopa and Levodopa | **Innovator** | Impax |
| **Dosage** | 61.25mg/ 245mg Capsule, extended release | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | More Than 5 |
| **Other ANDA developers** | More Than 5 | **Tentative Approvals** | More Than 5 |
| **Final Approvals** | None | **Generic Launches** | Less Than 5 |
| **Indication** | Indicated for Parkinsons disease | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.